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One sentence summary:  
Two reports in this edition of Cancer Discovery (1,2) outline how the genomic 
composition of tumors, including the presence of intragenic gene fusions, could 
inform the selection of treatment approaches in aggressive forms of the disease.    
Main text  
Despite the implementation of targeted therapy approaches in breast cancer, 
managing many of the aggressive forms of the disease still remains a challenge. For 
example, despite the improvements in survival that estrogen deprivation therapy has 
delivered for those with estrogen receptor positive (ER-positive) breast cancers, 
managing endocrine therapy resistant disease is complex. Likewise, identifying 
targeted approaches that are effective in those breast cancers that lack estrogen 
receptor, progesterone receptor and expression of the ERBB2 receptor, the so called 
“triple-negative breast cancers” (TNBCs), also remains challenging. One approach to 
these issues has been to take a precision medicine approach by customizing the 
treatment strategy based upon the precise molecular make-up of each individual’s 
disease.  
Whilst the delineation of breast cancer genomes and transcriptomes has heralded an 
era where this precision medicine approach can be much better implemented, one 
particular mutation type, intergenic fusions, i.e. chromosomal rearrangements that 
lead to fusions between two distinct genes, have received somewhat less attention 
than might be expected. This is largely because fusions were historically considered 
to be a feature of leukemias and sarcomas, and to have less influence upon 
carcinomas. Furthermore, the technical challenges associated with discriminating 
real fusion events from false positives are considerable and have limited large-scale 
discovery of intergenic fusions. This scenario has somewhat changed, with advances 
in techniques including Anchored Multiplex PCR (AMP), next generation sequencing 
and sequencing analytical pipelines now making fusion identification in breast 
cancers a more profitable exercise (3). For example, secretory carcinomas of the 
breast, a rare yet distinct form of TNBC, are driven by a t(12;15)(p13;q25) 
chromosomal translocation which encodes a transforming ETV6-NTRK3 gene fusion 
(4) (Figure 1). Likewise, adenoid cystic carcinomas of the breast are driven by a 
MYB-NFIB fusion caused by a t(6;9)(q22–23;p23–24) translocation (5). Other rare, 
yet recurrent, rearrangements in invasive ductal carcinomas of the breast have also 
been identified, including those associated with the MAST (microtubule-associated 
serine threonine) kinase and NOTCH gene family members (3). More recently, 
recurrent gain of function fusions involving the gene that encodes the alpha isoform 
of the estrogen receptor, ESR1 (e.g. ESR1-CCDC170), have been identified in 
aggressive ER-positive, luminal B, breast cancers; these fusions likely cause 
constitutive activity of ER (6). Next-generation sequencing studies have also 
identified a number of breast cancer gene fusions associated with other well-
established cancer driver genes including BRAF, and MET (7,8) (Figure 1).  
In this edition of Cancer Discovery, the labs of Ellisen (1) and Cantley (2) describe 
the identification of novel, therapeutically tractable oncogenic fusion genes in 
estrogen receptor positive and triple negative breast cancers, respectively. 
Importantly, both groups make the critical leap from identifying fusion events to 
functionally assessing how these mutations alter therapeutic responses.  
In the first report, Ellisen and colleagues used AMP to isolate fusion genes 
associated with 54 candidate genes in 110 patients with ER-positive breast cancer. 
This identified intragenic fusions associated with the kinase coding genes PIK3CA, 
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AKT3, RAF1 and also ESR1, consistent with prior reports (3). After confirming some 
of the fusion events in both primary and metastatic lesions by an orthogonal 
technology (fluorescent in situ hybridisation (FiSH)), Ellisen and colleagues used a 
panel of functional assays to establish that some of the fusions involving the RAF1, 
PIK3CA and AKT3 genes modulated phosphoprotein signalling via elevated 
phosphorylation of the downstream substrate RPS6 as well as estrogen-dependent 
growth in three-dimensional in vitro cultures of breast cancer. Importantly, the 
RPS6K1-AKT3 fusion also conferred resistance to estrogen withdrawal in mice 
bearing ER-positive tumor cell line xenografts. An analysis of clinical data suggests 
that fusions associate with PIK3CA, ESR1, RAF1 or AKT3 are relatively uncommon 
in primary disease but more frequent in metastatic ER-positive cancers. Furthermore, 
those with fusion positive tumors had a shorter overall survival when compared to 
those without fusions. In totality, Ellison’s work suggests that oncogenic fusions in 
ER-positive breast cancer could function as predictive biomarkers of clinical 
resistance to endocrine therapy.  
 
One interesting aspect of Ellisen’s work is the enhanced frequency of fusion events 
in metastatic disease, when compared to primary ER-positive cancer; this suggests 
that fusion genes might, in themselves, be a biomarker of advanced and aggressive 
disease. This association with metastatic disease might be expected, given the 
enhanced level of genomic alterations in this setting when compared to primary 
disease. Furthermore, a number of the fusion events that were private to metastatic 
lesions, and not found in patient matched primary lesions, were present prior to any 
treatment in the metastatic setting. Whether these are selected for by treatment of 
primary disease or exist in clones that have other fitness advantages remains to be 
seen. For many, the therapeutic aspects of this work will be of most interest; 
although the RPS6K1-AKT3 fusion was associated with endocrine therapy 
resistance, the combination of estrogen deprivation with the CDK4/6 inhibitor, 
palbociclib caused significant tumor growth suppression in vivo (1), suggesting that 
looking for this and similar fusions in biopsies from clinical trials assessing CDK4/6 
inhibitors with endocrine therapies might be informative. 
 
Ellison’s work is also notable in that, whilst most of the literature in the area of fusion 
genes in breast cancer has focused upon identifying fusions via DNA/RNA 
sequencing, there is much less emphasis given to demonstrating that the fusions 
identified are oncogenic or modulate therapy response. This is perhaps expected, 
given the technical challenges faced in experimentally recapitulating chromosomal 
translocations and the gene fusions they cause. The expression of cDNAs from 
expression constructs is normally the approach used to interrogate fusion gene 
function, and this can often be very informative. However, the ectopic pattern of gene 
expression often generated from a cDNA expression construct often does not 
replicate that seen in tumor cells with chromosomal translation. This is likely because 
endogenous gene promoters are rarely used with cDNAs, and because cDNAs are 
not transcribed from within the genomic context of the fusion gene. In models of 
acute myeloid leukaemia and Ewing's sarcoma, chromosomal translocations and the 
fusion genes they cause, have been engineered into cells by CRISPR-Cas9-
mediated gene editing (9), suggesting that this might also be an approach that could 
be applied to the study of breast cancer fusions. 
 
Compared to estrogen receptor-positive cancers, where targeted endocrine therapy 
is widespread but where drug resistance is a major challenge, in TNBC, identifying 
targeted therapies that work in significant numbers of patients is a significant issue. 
There might be a number of reasons for this; perhaps chief amongst these is the 
relative absence of unifying and targetable molecular features, such as ER or 
ERBB2 amplification, in the wide variety of TNBC patients. Although TNBC do 
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display some relatively recurrent molecular alterations (e.g. p53, Rb, NF1, BRCA1, 
PTEN or PIK3CA mutations, a series of copy number alterations, a basal-like 
transcriptomic signature etc.) strategies to target most of these do not exist. Instead 
inter-tumoral molecular heterogeneity is the pervading characteristic of TNBC; this 
has led many to think that the most effective approach to treating this disease is to 
take a fully personalised approach, and to target the almost unique set of molecular 
aberrations in each patient, rather than seeking therapeutic approaches that might 
work in many.  
Cantley and colleagues test the hypothesis that some of the relatively private gene 
mutations that occur in individual TNBCs provide therapeutic vulnerabilities (2). To 
do this, Cantley and colleagues carried out whole exome DNA sequencing and RNA 
sequencing from over 80 TNBCs that developed in genetically engineered mice with 
either a breast-lineage specific Tp53 mutation or a combination of Tp53 and Brca1 
mutations (2). Similar to previous studies using the same mouse models (10), the 
DNA/RNA profiling of TNBCs by Cantley and colleagues identified a recurrent basal-
like transcriptomic signature and Met oncogene amplification and in Tp53/Brca1 
mutant mouse tumors, an elevated level of genomic rearrangements. Reassuringly, 
the mutational spectrum seen in Tp53/Brca1 mutant tumors was most similar to the 
signature 3 profile associated with BRCA1 or BRCA2 mutations in human tumors. 
The two most notable discoveries, however, focussed upon: (i) fusion genes 
associated with a series of potentially oncogenic and targetable protein kinases such 
as Fgfr2 or Braf; and (ii) different tumors exhibiting distinct routes to the same 
dysregulated pathways, namely map-kinase (MAPK) or phopho-inositol-3-kinase 
(PI3K) signalling, a potential form of parallel evolution. In some cases, these fusions 
were shown to be essential for tumor cell fitness and also therapeutically exploitable; 
for example, in mice with Fgfr2-fusions, clinical FGFR inhibitors impeded tumor 
growth (2). 
 
One interesting aspect of Cantley’s work is that tumors with multiple distinct 
alterations, such as a tumor with both a Fgfr2 fusion and a Brca1 mutation, showed a 
better response to combination therapies that targeted both oncogenic drivers (e.g. a 
FGFR inhibitor plus a PARP inhibitor), than single agent approaches that only 
targeted one driver gene. The rationale for such an approach might appear at first 
sight to be self-evident, in that two drugs with distinct mechanisms of action, 
targeting different driver effects, are less unlikely to have overlapping mechanisms of 
resistance. However, whilst much of the field focusses upon identifying synergistic 
drug combinations that could be effective as cancer treatments, the approach of 
simultaneously targeting multiple driver lesions in the same tumor with additive 
combinations might be as, or even more, effective.  
  
Both Ellison and Cantley reports both highlight the potential of fusion genes as bona-
fide driver events and determinants of targeted therapy responses in breast cancer. 
The increasing technical advances in sequencing methodologies, especially those 
that aim to increase DNA read lengths, will undoubtedly enhance the ability to detect 
these events in the future. Moreover, incorporating fusion gene detection into the 
analysis of cell free DNA/circulating tumor cell DNA sequencing will provide the 
opportunity to monitor these events through the course of an individual patient’s 
clinical journey, information that could prove critical in the optimal selection and 
adjustment of treatment.  
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Figure legend  
Figure 1. Gene fusions in breast cancer. Schematic diagrams of oncogenic gene 
fusions identified in breast cancers. The breast cancer subtype and functional 
domains of the gene fusion are noted. 5’ and 3’ untranslated regions (UTR) are 
depicted by lighter colors. Vertical line indicates the chromosomal breakpoint.  
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